Cancer medicines
Brentuximab vedotin
Brentuximab vedotin
A lymphoma ADC delivering a drug through CD30 targeting.
Sources checked · Introductory guide
On this page
How it works
An antibody-drug conjugate linking a CD30 antibody to a microtubule inhibitor.[3]
Where it is used
Used in selected classic Hodgkin and CD30-associated lymphomas according to subtype and prior therapy.[1]
Key safety points
Report numbness, weakness or fever. A rare serious brain infection is possible; new confusion, speech, walking or vision changes need urgent assessment.[2]
Questions for your care team
- What is its role in my subtype, and how are neurological symptoms and infection monitored?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Brentuximab Vedotin (opens in a new tab)
- MedlinePlus · Brentuximab Vedotin (opens in a new tab)
- NCI Drug Dictionary · Brentuximab Vedotin (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.